Advanced wound management and personal healthcare devices manufactured to rigorous global medical standards
The global demand for high-quality, sterile ophthalmic formulations has experienced exponential growth. This surge is primarily driven by shifting demographic trends, including an aging global population, the ubiquity of digital screens causing digital eye strain (DES), and increasing environmental factors that exacerbate ocular surface diseases such as Dry Eye Syndrome (DES).
Consequently, pharmaceutical brands, healthcare providers, and distributors worldwide are increasingly seeking sterile Contract Development and Manufacturing Organizations (CDMO) that can deliver customized, regulatory-compliant ophthalmic solutions. Ophthalmic manufacturing requires absolute sterility, high precision in formulation, and advanced container closure systems to prevent contamination without compromising product efficacy.
Entering the ophthalmic care market requires traversing strict regulatory landscapes. Ophthalmic products are classified as high-risk sterile products, governed closely by organizations such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), National Medical Products Administration (NMPA) in China, and Therapeutic Goods Administration (TGA) in Australia.
Manufacturing facilities must comply with strict Current Good Manufacturing Practices (cGMP) and hold certifications like ISO 13485 (Medical Devices Quality Management Systems). As an OEM/ODM buyer, partnering with a factory possessing pre-established international certifications drastically reduces time-to-market and mitigates compliance risks, allowing brands to launch products with scientific validation.
Decades of excellence in advanced medical materials and sterile technology
Hubei ProMix Medical Co., Ltd. is a modern high-tech enterprise integrating research and development, manufacturing, sales, and service of advanced medical materials. Founded in 2002 and located in Huazhong International Industrial Park, ProMix Medical has grown into a diversified industrial group with more than ten wholly owned subsidiaries, covering sectors such as medical technology, medical devices, biopharmaceuticals, and research institutes. Backed by over 20 years of industry experience, the company has established a strong foundation in innovation and product development.
ProMix Medical holds more than 100 intellectual property rights, including invention patents and utility model patents. The company has passed multiple international quality management system certifications such as ISO 13485, ISO 9001, ISO 14001, and ISO 45001. Its products are certified by global regulatory authorities including CE, FDA, TGA, and HSA, and are exported to over 170 countries and regions worldwide. In the domestic market, the company holds nearly 100 NMPA certifications and serves more than 20,000 medical institutions.
Strategic Growth Director Insight: Innovation and quality excellence have earned ProMix Medical wide recognition from government authorities and industry organizations. It has been honored with titles such as "High-Tech Enterprise," "Intellectual Property Advantage Enterprise," "Gazelle Enterprise," and "Specialized and Sophisticated ‘Little Giant’ Enterprise." The company also plays an active role in industry development as a key member and leader in multiple research and innovation alliances related to traditional and modern medical therapies.
Bridging traditional medical wisdom with modern scientific manufacturing technology
Building a professional platform for a harmonious and healthy industry ecosystem by delivering compliant and reliable healthcare raw materials and customized consumer products.
A leading Chinese expert in medical plasters and wound dressing solutions, scaling capability to target sterile eye drops development, formulation research, and global CDMO distribution.
Focusing on green technology, caring for life and health, and aiming to become the preferred innovative brand in the global health industry driven by rigorous science and technology.
ProMix Medical is committed to promoting a modern, innovative, and technology-driven healthcare philosophy rooted in the wisdom of traditional Chinese medicine. By integrating advanced scientific research with traditional healing concepts, the company develops safe, effective, and high-quality healthcare products.
With a focus on purity, innovation, and technological excellence, ProMix continuously delivers products that meet evolving global healthcare standards. The brand reflects not only technological advancement but also a deep commitment to improving quality of life, representing a harmonious blend of tradition, innovation, and human-centered care.
A comprehensive visual overview of our industrial manufacturing steps, cutting, laminating, and advanced packaging infrastructure
A strategic breakdown of manufacturing pathways for global eye drop distribution
We work with brand product managers to design custom liquid eye drop formulations. Our technology accommodates viscous artificial tears (utilizing Sodium Hyaluronate or Carboxymethylcellulose), allergy relief solutions, redness relievers, and natural, traditional Chinese medicine-infused botanical eye formulations. Our R&D team ensures optimal pH, osmolarity, and bio-compatibility parameters.
Ophthalmic safety hinges on the filling environment. Our production lines feature Blow-Fill-Seal (BFS) technology or high-speed sterile multi-dose preservative-free (MDPF) vial filling. These processes minimize human intervention, producing container closures that sustain formulation integrity without the addition of harsh preservatives that cause dry eye irritation.
Every single batch undergoes stringent microbiological testing, particulate testing, stability assessment, and container integrity verification. Backed by our ISO 13485 and ISO 9001 quality system certifications, we guarantee that all OEM/ODM shipments match national pharmacopeia standards, simplifying global customs custom clearances.
Adapting manufacturing parameters to emerging consumer expectations and regulatory landscapes
Consumers are demanding preservative-free alternatives because traditional preservatives (like Benzalkonium Chloride) can trigger ocular surface inflammation over prolonged usage. The industry is rapidly pivoting toward advanced multi-dose dropper systems featuring mechanical valves and sterile microbiological filters that prevent backflow of pathogens into the bottle. Our engineering lines are actively adapting to assemble these next-generation dropper heads.
Standard aqueous eye drops exhibit low ocular retention times due to blink-drainage. To overcome this limitation, our CDMO research is heavily invested in lipid-based nano-emulsions and bio-adhesive hydrogel technologies. By increasing eye-surface contact duration, these advanced delivery methods enhance active ingredient absorption, achieving therapeutic target objectives with lower dosage concentration profiles.
Aligned with our core corporate philosophy of "Focusing on green technology and caring for life and health," we are researching bio-based recyclable materials for single-dose strip vials and outer cardboard boxes. Integrating sustainable materials without compromising sterile barriers represents the future of medical manufacturing. We assist brands in calculating and optimizing their carbon footprint across the supply chain.
Our packaging facilities utilize AI visual recognition cameras to identify particle contamination, misprinted labeling, or microscopic physical defects in bottle seals. Automated optical inspection (AOI) prevents human errors, ensuring a zero-defect output for all OEM/ODM partners distributing to sensitive regulated international markets.
Matching dynamic customer needs with custom targeted formulation solutions
Target Group: Office professionals, programmers, and gamers.
Formulation Type: Osmoprotective lubricating drop utilizing Hyaluronic Acid and Glycerin to mimic natural tear film and provide lasting hydration.
Target Group: Urban residents and seasonal allergy sufferers.
Formulation Type: Decongestant-free anti-itch solutions, leveraging natural antihistamine elements and soothing botanical ingredients.
Target Group: Athletes, swimmers, and outdoor enthusiasts.
Formulation Type: Electrolyte-balanced, sterile moisturizing drops targeting minor ocular irritation caused by wind, UV rays, or chlorinated water.
Answering major business, technical, and regulatory questions from procurement managers
Advanced, skin-friendly medical formulations developed with advanced polymers and thermal technologies
ProMix Medical
